SCHEMBL535809

SCHEMBL535809

OCc1c(-c2ccccc2)noc1C=Cc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NOTUM Q6P988 4/20 0.41
PTGS2 P35354 3/20 0.39
PTGS1 P23219 2/20 0.39
MAPK1 P28482 2/20 0.39
ALDH1A1 P00352 3/20 0.39
TDO2 P48775 1/20 0.38
GABRA5 P31644 3/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
LMNA P02545 1/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
GAA P10253 1/20 0.37
CASP3 P42574 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL535808 1.00 RAB9A (0.42) RAB9ANPC1SMN1; SMN2TDP1L3MBTL1
SCHEMBL286313 0.90 KMT2A (0.48) NPC1L3MBTL1NOTUMALDH1A1GABRA5
SCHEMBL286527 0.90 CASP3 (0.48) RAB9ANPC1SMN1; SMN2TDP1L3MBTL1
SCHEMBL286528 0.90 CASP3 (0.48) RAB9ANPC1SMN1; SMN2TDP1L3MBTL1
SCHEMBL286314 0.90 KMT2A (0.48) NPC1L3MBTL1NOTUMALDH1A1GABRA5
SCHEMBL535869 0.84 HTR7 (0.38) RAB9ANPC1L3MBTL1NOTUMPTGS2
SCHEMBL535868 0.84 HTR7 (0.38) RAB9ANPC1L3MBTL1NOTUMPTGS2
SCHEMBL535835 0.82 GABRA5 (0.42) RAB9ANPC1SMN1; SMN2TDP1L3MBTL1
SCHEMBL535834 0.82 GABRA5 (0.42) RAB9ANPC1SMN1; SMN2TDP1L3MBTL1
SCHEMBL535806 0.78 GABRA5 (0.43) RAB9ANPC1L3MBTL1GABRA5MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2414354-B1 Hydroxy-methyl isoxazole derivatives as gaba a modulators HOFFMANN LA ROCHE (CH) 2012-12-12 EP disclosed
US-8222246-B2 Substituted isoxazoles HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
EP-2414354-A1 Hydroxy-methyl isoxazole derivatives as gaba a modulators F. Hoffmann-La Roche AG (CH) 2012-02-08 EP disclosed
WO-2010112475-A1 HYDROXY-METHYL ISOXAZOLE DERIVATIVES AS GABA A MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-07 WO disclosed
US-20100256127-A1 SUBSTITUTED ISOXAZOLES ROCHE PALO ALTO LLC 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256127-A1 SUBSTITUTED ISOXAZOLES GABRA5, GABRA1, GABRA3 RAB9A 1526/4885NPC1 1638/4885SMN1; SMN2 3006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.